Where Intra-Cellular Therapies Stands With Analysts
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ: ITCI) has received varied analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased to $91.57, reflecting a positive outlook. The company has shown significant revenue growth but faces challenges in profitability and return metrics.
June 12, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has received predominantly bullish ratings from analysts, with an average 12-month price target of $91.57, up from $83.10. The company has shown strong revenue growth but struggles with profitability and return metrics.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. However, the company's profitability and return metrics are below industry standards, which could temper the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100